Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
:FGEN
FGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.18 - $1.53
Previous CloseN/A
Volume937.77K
Average Volume (3M)644.40K
Market Cap
$29.69M
Enterprise Value-$1.48M
Total Cash (Recent Filing)$33.61M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 11, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding101,043,970
10 Day Avg. Volume664,295
30 Day Avg. Volume644,401
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-0.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.42
Enterprise Value/Market Cap-0.05
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit0.11
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.00Price Target Upside3348.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
FibroGen News
PremiumCompany Announcements
FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes
PremiumCompany Announcements
FibroGen Reports Q1 2025 Earnings and Strategic Updates
PremiumPre-Earnings
Is FGEN a Buy, Before Earnings?
PremiumCompany Announcements
FibroGen’s Earnings Call: Strategic Moves Amid ChallengesBulls Say, Bears Say
Bulls Say
Financial HealthThe anticipated extension of the company's cash runway strengthens its overall current and future financial health.
Regulatory ProgressManagement conveyed that interactions with the FDA have progressed in a timely manner with no delays, despite investor uncertainties.
Strategic TransactionsThe sale of FibroGen China to AstraZeneca is considered a strategic transaction, providing FibroGen with additional capital and streamlining its portfolio.
Bears Say
Legal And Financial PenaltiesAnnounced a settlement related to roxadustat, which will result in a $1.25 million civil penalty paid to FibroGen.
Operational ChallengesThe focus remains on Pamrevlumab, especially after the latest Roxa setback, indicating continued strategic pipeline development.
Uncertain TimelinesFeedback from meeting with the FDA to discuss next steps for roxadustat in anemia associated with low-risk myelodysplastic syndrome now expected in the third quarter.
Ownership Overview
1.78% Insiders
10.90% Mutual Funds
13.04% Other Institutional Investors
69.52% Public Companies and Individual Investors
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $0.18 and its highest was $1.53 in the past 12 months.
What is FibroGen’s market cap?
FibroGen’s market cap is $29.69M.
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Aug 11, 2025 which is in 68 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on May 12, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.02.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -0.09.
How many shares outstanding does FibroGen have?
FibroGen has 101,043,970 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of $0.05 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of FibroGen?
Currently, no hedge funds are holding shares in FGEN
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (3348.28% Upside)
$10.00 (3348.28% Upside)
Blogger Sentiment
Bearish
FGEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 875.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $153.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.5%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.58%
12-Months-Change
Fundamentals
Return on Equity
60.38%
Trailing 12-Months
Asset Growth
-54.84%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc. (FGEN) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs. Headquartered in San Francisco, California, FibroGen focuses primarily on innovative products for anemia, fibrotic diseases, and cancer. The company's core products include roxadustat, an oral small molecule inhibitor for anemia associated with chronic kidney disease, and pamrevlumab, a monoclonal antibody for the treatment of fibrotic diseases and certain cancers.
FGEN Company Deck
FGEN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a transformative period for FibroGen, with the sale of FibroGen China to AstraZeneca bringing in higher than expected proceeds and extending their financial runway significantly. There is notable progress in their clinical pipeline, particularly in the development of FG-3246 and FG-3180, with promising results from clinical trials. However, the company faced a significant decline in revenue and continued to operate at a net loss. While the highlights indicate strategic advancements and positive financial prospects, the revenue decline and continued net loss are concerning.Read More>FGEN Stock 12 Month Forecast
Average Price Target
$10.00
▲(3348.28%Upside)